Cardiol Therapeutics Inc. Year-End 2025 Update on Operations

Cardiol Therapeutics Inc. announced its year-end 2025 operational update, highlighting significant progress in its clinical trials and strategic advancements. The company initiated its pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis, surpassing 50% patient enrollment with full enrollment expected in Q2 2026. Positive Phase II ARCHER data demonstrated CardiolRx™'s efficacy in reducing left ventricular mass in acute myocarditis patients, with results published in ESC Heart Failure. The CRD-38 program advanced towards Investigational New Drug (IND) application and Phase I clinical development. Cardiol secured U.S. patent allowance for CardiolRx™ and CRD-38, broadly protecting their use in cardiac conditions until late 2040. The company also strengthened its Board of Directors with Dr. Timothy Garnett's election and raised $31 million, ensuring a cash runway into Q4 2027. The company is well-funded to complete the MAVERIC trial and plans to initiate CRD-38 clinical development, further strengthening its product pipeline.